U.S. pharma large copyright scrapped two experimental weight loss products last calendar year—a the moment-daily pill, lotiglipron, due to elevated liver enzymes in addition to a two times-day by day tablet, danuglipron, as a result of sturdy Uncomfortable side effects—but CEO Albert Bourla has said the company is set to “Perform and earn”